- Home
- CNSP vs ADVB Comparison
CNSP vs ADVB Comparison
Compare CNSP & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | ADVB |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNSP | ADVB |
|---|---|---|
| Price | $4.75 | $4.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 16.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.19 |
| 52 Week High | $10.59 | $7.70 |
Technical Indicators
Market Signals| Indicator | CNSP | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 55.38 |
| Support Level | $4.50 | $3.71 |
| Resistance Level | $5.61 | $5.59 |
| Average True Range (ATR) | 0.33 | 0.47 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 97.50 | 78.57 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.